ARTICLE | Clinical News
JNJ-Q2: Phase II data
November 15, 2010 8:00 AM UTC
Top-line data from a double-blind, U.S. Phase II trial in 161 patients showed that twice-daily 250 mg oral JNJ-Q2 for 7-14 days missed the primary endpoint of non-inferiority to twice-daily 600 mg Zy...